BeijijngIn May 2018 the first China-Europe Symposium, jointly organised by the BBDiag consortium and its Chinese partner, was successfully held in Beijing, China. The Joint Beijing Symposium is one of the events within the network with an international dimension and with an aim to promote research collaboration with China in early Alzheimer’s Disease diagnostic technology. The symposium was attended by over 50 researchers in the field from China, Europe and the rest of the world.  Ten BBDiag Early Stage Researchers, some supervisors and Project Coordinator Professor Genhua Pan travelled to Beijing to deliver talks on their research topics and discuss their findings. Some ESRs who could not attend the symposium in person had given their talks via Skype. Local organizer Prof. Yi Tang from Xuan Wu Hospital organised for experts from China and Hong Kong to attend and deliver talks on the advancements and research they have made in early diagnostics for AD and also students from the Xuan Wu Hospital.

The event was opened with a talk by the highly esteemed Prof. Jianping Jia of Xuan Wu Hospital Capital Medical Hospital. Over the next two days subject specific talks were delivered by invited experts in the field of AD diagnosis and biomarkers, BBDiag ESR’s and PI’s.  These talks sparked and encouraged fruitful discussions amongst the audience and experts, raised interesting and challenging points with prospects for future collaborations.

Prof Yi Tang also organised and hosted a wonderful welcome meal, which allowed all attendees the opportunity to continue their fruitful conversations.

Finally, the ESR’s and PI’s after an informative and constructive two day symposium had a once in a life time experience and visited the Great Wall of China, one of the seven wonders of the world!

Residential workshop in Rome

held at the Sapienza University of Rome, Italy (March 19th-21st, 2018)

Residential workshop in Swansea

held at the Swansea University, Wales (September 11th-15th, 2017)


During the “Rome Training Meeting” of the European Horizon2020 Marie Skłodowska Curie project “Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease” held at the Sapienza University of Rome (March 19th-21st, 2018), senior and early stage researchers of several Countries have discussed a new plan for the monitoring of blood biomarkers, cognitive functions, and lifestyle in patients with Alzheimer’s disease by innovative graphene-based devices and information and communication technology services.

The local organizer, Prof. Claudio Babiloni (Department of Physiology and Pharmacology “Erspamer”, Sapienza University of Rome), opened the Meeting introducing the concept of “Italian Baroque” as a useful metaphor in the battle against Alzheimer’s disease. External Lecturers of the Meeting dealt with important challenges in the battle against Alzheimer’s disease. Prof. Ferdinando Nicoletti (Sapienza University of Rome) depicted a new provocative scenario where the pathophysiological diagnostic biomarker of Alzheimer’s disease (i.e. amyloid beta 1-42 protein) and its underlying biological substrate may represent a physiological resource rather than an enemy in the drug discovery pathway. Dr. Fulvio Galeazzi and Dr. Valeria Ardizzone (GARR, Italy) described the significant resource of innovative biomedical services of the GARR platform “DECIDE” for the biomarker-based diagnosis of Alzheimer’s disease. Finally, Prof. Laura Bonanni (University of Chieti, Italy) emphasized the issue of specificity in the discovery of new biomarkers of Alzheimer’s disease, especially at the border with other progressive neurodegenerative disorders such as Parkinson’s and Lewy Body diseases.

During the Meeting, all early stage researchers and their mentors (see the Meeting Agenda in the following) presented main objectives, milestones, and deliverables of investigations planned in the BBDiag project. The discussion was very fruitful paving the plan of secondments of the early stage researchers and shared protocols, databases, analysis tools, and other resources (including those for exploitation of the discoveries in the reference market) for successful research along the project. In this context, these researchers will be involved in the development of graphene-based devices for the measurement of new blood biomarkers in mouse models of Alzheimer’s disease and selected seniors with preclinical (before cognitive deficits) or prodromal (mild cognitive deficits) stages of that disease.

The Coordinator of BBDiag project, Prof. Genhua Pan (University of Plymouth), chaired the general discussion of the project towards its ambitious objectives.

The Meeting was video recorded and enriched by short interviews to all early stage researchers, mentors, and external lecturers for the dissemination of the core messages through social media in the coming weeks. During the pauses of the Meeting (e.g. coffee breaks), pictures and music of Italian Baroque livened up the environment. Furthermore, a lecture entitled “Italian Baroque in Music” was held by M° Stefano Rotondi (flute) and Ms. Rebecca Rotondi (cello) before the social dinner of March 20th.



Mr. Bin Gao was born and grew up in Hebei Province, China. He received his Bachelor’s Degrees in Management from the Tianjin University, China in 2012 and Master of Science Degree in Management from Purdue University (USA) in 2013. He also obtained his Master’s Degree in Finance from Tianjin University, China in 2015. After his graduation, he worked as a Research Analyst Futures First Investment Consulting Co. Ltd., China. He has been awarded as the designation of Chartered Financial Analysts by the CFA Institute (USA). His current research interests include business with management, finance, and business model innovation. His goal is to apply his knowledge and skills to develop an innovative business model that will commercialize the technology development of the early diagnosis of Alzheimer’s disease in order to improve the overall quality of life and add value to society.